2.78
-0.25 (-8.25%)
| Penutupan Terdahulu | 3.03 |
| Buka | 3.06 |
| Jumlah Dagangan | 1,211,147 |
| Purata Dagangan (3B) | 2,604,235 |
| Modal Pasaran | 249,978,160 |
| Harga / Jualan (P/S) | 5.66 |
| Harga / Buku (P/B) | 12.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -758.05% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 310.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.88% |
| Nisbah Semasa (MRQ) | 3.08 |
| Aliran Tunai Operasi (OCF TTM) | -208.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -103.52 M |
| Pulangan Atas Aset (ROA TTM) | -36.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -140.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Editas Medicine, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.33% |
| % Dimiliki oleh Institusi | 57.56% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (Baird, 115.83%) | Beli |
| Median | 5.50 (97.84%) | |
| Rendah | 5.00 (HC Wainwright & Co., 79.86%) | Beli |
| Purata | 5.50 (97.84%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Aug 2025 | 5.00 (79.86%) | Beli | 3.03 |
| Baird | 13 Aug 2025 | 6.00 (115.83%) | Beli | 3.08 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Aug 2025 | Pengumuman | Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate |
| 27 Aug 2025 | Pengumuman | Editas Medicine to Participate in Upcoming Investor Conferences |
| 12 Aug 2025 | Pengumuman | Editas Medicine Announces Second Quarter 2025 Results and Business Updates |
| 12 Jun 2025 | Pengumuman | Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |